Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Posterior chamber

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: Posterior chamber. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-001589-15 Sponsor Protocol Number: BLP 415-007 Start Date*: 2005-09-15
    Sponsor Name:Bausch & Lomb Incorporated
    Full Title: A multi-center study evaluating the safety of a replacement intravitreal fluocinolone acetonide (FA) (0.59 mg) implant in patients with non-infectious posterior uveitis who were previously treated ...
    Medical condition: Non-infectious Uveitis affecting posterior segment of the eye
    Disease: Version SOC Term Classification Code Term Level
    4.1 10036370 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001622-29 Sponsor Protocol Number: ALI-P01-21-006 Start Date*: 2023-03-01
    Sponsor Name:Alimera Sciences Europe Limited
    Full Title: A NON-RANDOMISED, OPEN-LABEL, UNCONTROLLED, MULTI-CENTRE, PHASE IIIB STUDY EVALUATING THE SAFETY AND EFFICACY OF FLUOCINOLONE ACETONIDE 190 MICROGRAMS INTRAVITREAL IMPLANT IN PAEDIATRIC SUBJECTS FR...
    Medical condition: Non-Infectious Uveitis affecting the posterior segment
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10036370 Posterior uveitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016008-22 Sponsor Protocol Number: M10-880 Start Date*: 2010-07-19
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis
    Medical condition: Inactive non-infectious intermediate-, posterior-, or pan-uveitis.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022557 Intermediate uveitis LLT
    12.1 10033687 Panuveitis LLT
    12.1 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) BE (Completed) PT (Completed) GB (Completed) NL (Completed) DE (Completed) DK (Completed) AT (Completed) IT (Completed) CZ (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-016095-68 Sponsor Protocol Number: M10-877 Start Date*: 2010-07-19
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non infectious...
    Medical condition: Active Non-infectious Intermediate-, Posterior-, or Pan-uveitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022557 Intermediate uveitis LLT
    12.1 10033687 Panuveitis LLT
    12.1 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) BE (Completed) PT (Completed) GB (Completed) NL (Completed) DE (Completed) DK (Completed) AT (Completed) IT (Completed) CZ (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-011237-27 Sponsor Protocol Number: CAIN457C2303 Start Date*: 2009-10-15
    Sponsor Name:Novartis Pharma Services Ag
    Full Title: A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated ...
    Medical condition: Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) FR (Completed) DE (Completed) AT (Prematurely Ended) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003254-90 Sponsor Protocol Number: CLFG316A2204 Start Date*: 2012-05-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomised, active-controlled, open-label, multiple-dose, proof-of-concept study of intravitreal LFG316 in patients with active non-infectious intermediate-, posterior-, or panuveitis requiring s...
    Medical condition: Active non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000161411 10022557 Intermediate uveitis LLT
    20.0 100000014975 10033687 Panuveitis LLT
    20.0 100000015065 10036370 Posterior uveitis LLT
    20.0 100000014975 10066681 Acute uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014834-22 Sponsor Protocol Number: CAIN457C2302 Start Date*: 2010-07-06
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio Fase III, multicéntrico, aleatorizado con doble enmascaramiento, controlado con placebo, de determinación de dosis y 28 semanas de duración, para evaluar AIN457 frente a placebo en la induc...
    Medical condition: determinación de dosis y 28 semanas de duración, para evaluar AIN457 frente a placebo en la inducción y mantenimiento de la supresión de la uveítis en adultos con uveítis activa no infecciosa inter...
    Disease: Version SOC Term Classification Code Term Level
    11 10022557 Uveítis intermedia PT
    11 10036370 Uveítis posterior LLT
    11 10033687 Panuveítis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) HU (Prematurely Ended) GB (Completed) DE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001243-67 Sponsor Protocol Number: CAIN457A2208 Start Date*: 2011-07-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label proof-of-concept study with a double-masked, dose-ranging component to assess the effects of AIN457 in patients with noninfectious uveitis
    Medical condition: Intermediate, posterior or pan-uveitis of noninfectious origin
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    14.0 10015919 - Eye disorders 10036370 Posterior uveitis LLT
    14.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019246-11 Sponsor Protocol Number: 577 Start Date*: 2010-07-15
    Sponsor Name:Bausch & Lomb Incorporated
    Full Title: A Randomized, Multicenter, Double-Blind, Parallel-Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate Ophthalmic Gel, 0.5% versus Vehicle for the Treatment of Inflammation and Pa...
    Medical condition: Inflammation and pain following cataract surgery
    Disease: Version SOC Term Classification Code Term Level
    13.0 10015943 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002647-35 Sponsor Protocol Number: C-04-65 Start Date*: 2005-10-06
    Sponsor Name:Alcon Research, Ltd
    Full Title: Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo (Nepafenac Vehicle) for the Prevention and Treatment of Ocular Inflammation and Ocular Pai...
    Medical condition: ocular pain and inflammation associated with cataract extraction and intraocular lens implantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) ES (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001609-25 Sponsor Protocol Number: X052131/CL3-78989-006 Start Date*: 2013-01-02
    Sponsor Name:XOMA (US) LLC
    Full Title: A RandomizEd, Double-masked, Placebo-controlled Study of the SafetY and Efficacy of GevokizUmAb in the TReatment of Subjects with Non-infectious IntermeDiate, Posterior, or Pan- uveitis Currently C...
    Medical condition: Non-infectious Intermediate, Posterior, or Pan- Uveitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    17.0 10038359 - Renal and urinary disorders 10069034 Tubulointerstitial nephritis and uveitis syndrome PT
    17.0 100000004862 10036370 Posterior uveitis LLT
    17.0 100000004866 10071139 Behcet's uveitis LLT
    17.0 10015919 - Eye disorders 10042745 Sympathetic uveitis LLT
    17.0 10015919 - Eye disorders 10012692 Diabetic uveitis PT
    17.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) PT (Completed) IT (Completed) GR (Prematurely Ended) ES (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011913-26 Sponsor Protocol Number: 588 Start Date*: 2010-03-10
    Sponsor Name:Dr. Gerhard Mann chem.-pharm Fabrik GmbH
    Full Title: A Randomized, Multicenter, Double-Masked, Parallel-Group Dose Ranging Clinical Safety and Efficacy Evaluation of BOL-303242-X Ophthalmic Suspension versus Vehicle for the Treatment of Inflammation ...
    Medical condition: inflammation of the eye follwoing cataract surgery
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015943 Eye inflammation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014835-19 Sponsor Protocol Number: CAIN457C2301 Start Date*: 2010-02-15
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio Fase III, multicéntrico, aleatorizado con doble enmascaramiento, controlado con placebo, de determinación de dosis y 24 semanas de duración, con el objetivo de evaluar el AIN457 frente a pl...
    Medical condition: Demostrar la eficacia y seguridad de AIN457 como terapia adyuvante en el tratamiento de la uveitis intermedia, uveitis posterior o panuveitis que precise inmunosupresión sistémica.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10022941 Iridocyclitis LLT
    9 10022557 Intermediate uveitis LLT
    9 10033687 Panuveitis LLT
    9 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003243-37 Sponsor Protocol Number: Start Date*: 2017-11-02
    Sponsor Name:MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health
    Full Title: Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial
    Medical condition: Uveitic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10002709 Anterior uveitis LLT
    22.1 10015919 - Eye disorders 10022557 Intermediate uveitis LLT
    20.1 100000004862 10036370 Posterior uveitis LLT
    20.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    20.1 10015919 - Eye disorders 10058202 Cystoid macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2009-015509-38 Sponsor Protocol Number: CAIN457C2302E1 Start Date*: 2010-10-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 34-week extension to a 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppres...
    Medical condition: Non-infectious, intermediate uveitis, posterior uveitis or panuveitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000737-36 Sponsor Protocol Number: 206207-015 Start Date*: 2006-05-17
    Sponsor Name:Allergan Limited
    Full Title: A 6-Week, Multicenter, Masked, Randomized Trial (with a 20-Week Masked Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS...
    Medical condition: Non-infectious ocular inflammation of the anterior segment in anterior uveitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) BE (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000304-29 Sponsor Protocol Number: Start Date*: 2016-04-05
    Sponsor Name:MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health
    Full Title: Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial
    Medical condition: Uveitic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014995 10002709 Anterior uveitis LLT
    20.0 100000161411 10022557 Intermediate uveitis LLT
    20.0 100000014975 10033687 Panuveitis LLT
    20.0 100000015065 10036370 Posterior uveitis LLT
    20.0 10015919 - Eye disorders 10058202 Cystoid macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015508-24 Sponsor Protocol Number: CAIN457C2301E1 Start Date*: 2010-02-15
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Extensión de 38 semanas del Estudio Fase III, multicéntrico, aleatorizado con doble enmascaramiento, controlado con placebo, de determinación de dosis y 24 semanas de duración, con el objetivo de e...
    Medical condition: Terapia adyuvante para el tratamiento de uveitis intermedia, uveitis posterior o panuveitis que precisen inmunosupresión sistémica
    Disease: Version SOC Term Classification Code Term Level
    12.0 10022941 Iridocyclitis LLT
    9 10022557 Intermediate uveitis LLT
    9 10033687 Panuveitis LLT
    9 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001810-14 Sponsor Protocol Number: PSV-FAI-001 Start Date*: 2013-10-30
    Sponsor Name:pSivida Corporation
    Full Title: A PHASE III, MULTI-NATIONAL, MULTI-CENTER, RANDOMIZED, MASKED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A FLUOCINOLONE ACETONIDE INTRAVITREAL (FAI) INSERT IN SUBJECTS WITH CHRONIC NON-INFECTIOUS...
    Medical condition: chronic non-infectious uveitis affecting the posterior segment of the eye
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002066-39 Sponsor Protocol Number: REPEXStudy Start Date*: 2013-09-04
    Sponsor Name:Azienda Ospedaliera di Reggio Emilia Arcispedale "S.Maria Nuova"/IRCCS
    Full Title: The Reggio Emilia study on bromfenac for patients with PseudoEXfoliation syndrome undergoing cataract surgery: the REPEX study
    Medical condition: Postoperative inflammation in patients with pseudoexfoliatio lentis undergoing cataract surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 23:57:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA